Clinical trials: Prostate Cancer, pill or tablet or capsule or oral, open to volunteers
- Condition Prostate Cancer
- Drug or intervention pill OR tablet OR capsule OR oral
- Status Open to volunteers
Prostate Cancer (CRPC)
Safety, Efficacy and Pharmacokinetics of TT00420 Tablets Combined With Novel Endocrine Therapy in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
The goal of this clinical trial is to learn if tinengotinib combined with darolutamide or enzalutamide works to treat participants with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior androgen…
- Trial name
- NCT07871110
- Testing
- tinengotinib 10 mg QD plus darolutamide, tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide, tinengotinib 10 mg QD plus enzalutamide
- Where
- 16 sites in China
- Volunteers
- 182 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer, Prostate Cancer, Prostate Cancer (Adenocarcinoma)
- Trial name
- MODeFIRe-1 (NCT07745361)
- Testing
- Oral MRT-2359, Apalutamide
- Where
- 14 sites in United States
- Volunteers
- 25 people
- Sponsor
- Monte Rosa Therapeutics, Inc
Metastatic Prostate Cancer
Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer
The purpose of this clinical trial is to determine the anti-tumor activity of talazoparib plus enzalutamide as first line treatment for metastatic castration resistant prostate cancer (mCRPC) in participants whose disease has…
- Trial name
- TEAM PC (NCT06582628)
- Testing
- Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule
- Where
- 19 sites in France, Spain
- Volunteers
- 78 people
- Sponsor
- Fundacion Oncosur
Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT06801236
- Testing
- ACE-232 tablets
- Where
- 13 sites in United States, China
- Volunteers
- 88 people
- Sponsor
- Acerand Therapeutics (Hong Kong) Limited
Prostate Cancer
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and…
- Trial name
- NCT07711184
- Testing
- HRS-7525 tablets
- Where
- 7 sites in Australia, China
- Volunteers
- 320 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.
- Trial name
- NCT06568094
- Testing
- HRS-5041 tablets, Abiraterone Acetate tablets（II）, Prednisone Acetate tablets
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer, Prostate Adenocarcinoma
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy.
- Trial name
- NCT05726292
- Testing
- Relacorilant, Enzalutamide, Androgen Deprivation Therapy
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Chicago
Advanced Prostate Cancer
Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of HRS-5041 in men with progressive metastatic castration resistant prostate cancer.
- Trial name
- NCT05942001
- Testing
- HRS-5041, Docetaxel injection, Abiraterone acetate tablets
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Cancer
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
The objective of this study is to see if providing an appropriate therapy based on the genomic testing of prostate tumour tissue will result in an improved clinical response.
- Trial name
- GUNS (NCT04812366)
- Testing
- Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab
- Where
- 9 sites in United States, Canada
- Volunteers
- 315 people
- Sponsor
- University of British Columbia
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
This phase I/II trial tests the safety, side effects, and best dose of abemaciclib and whether it works before 177Lu-PSMA-617 in treating patients with castration resistant prostate cancer that has spread to other places in the…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- UPLIFT (NCT05113537)
- Testing
- Abemaciclib, Lutetium Lu 177-PSMA-617
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Vadim S Koshkin
Prostate Cancer, Radiation Toxicity
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
This study will establish the preferred dose of lisinopril in men with non-metastatic prostate cancer undergoing radiation treatment.
- Conditions
- Prostate Cancer, Radiation Toxicity, Urinary Complication
- Trial name
- NCT05530655
- Testing
- Lisinopril Tablets
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Rochester
Prostate Cancer (Post Prostatectomy)
Adjuvant Rezvilutamide Monotherapy for High-Risk Prostate Cancer After Radical Prostatectomy
Prostate cancer patients with high-risk features who undergo radical prostatectomy (RP) are at a significant risk of biochemical recurrence (BCR) and disease progression.
- Trial name
- ARMOR (NCT07711314)
- Testing
- Rezvilutamide Tablets
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Metastatic Hormone-Sensitive Prostate Cance
Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate Cancer
GUARD-QUANTUM is a prospective, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study. The rationale behind studying this combination lies in the potential additive or synergistic benefits that may arise…
- Trial name
- GUARD-QUANTUM (NCT07717099)
- Testing
- Ra223, Darolutamide Oral Tablet, Androgen Deprivation Therapy (ADT)
- Where
- 12 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Metastatic Prostate Cancer
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
- Trial name
- NCT05413421
- Testing
- ORIC-944, Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets, Apalutamide (Erleada™) 60 mg or 240 mg tablets
- Where
- 27 sites in United States, Australia and 2 more
- Volunteers
- 275 people
- Sponsor
- ORIC Pharmaceuticals
Castration-Resistant Prostate Cancer (CRPC)
Safety, Tolerability, and Efficacy of CP-PCA07 in Combination With Enzalutamide in Patients With Castration-Resistant Prostate Cancer
The purpose of this clinical study is to evaluate the safety, tolerability, and efficacy of CP-PCA07 in combination with enzalutamide in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT07683013
- Testing
- CP-PCA07, Enzalutamide 40 mg capsule
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Hyundai Bioscience Co., Ltd.
Metastatic Hormone-sensitive Prostate Cancer
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
This is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with docetaxel plus apalutamide and ADT, assessed by event-free survival, in patients with mHSPC who do not…
- Trial name
- REINFORCE (NCT07333066)
- Testing
- Apalutamide (Erleada™) 60 mg or 240 mg tablets, Docetaxel
- Where
- 56 sites in France, Germany and 3 more
- Volunteers
- 320 people
- Sponsor
- Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Prostate Cancer
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
- Trial name
- NCT03769766
- Testing
- Curcumin
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.
- Trial name
- NCT07241416
- Testing
- Rezvilutamide Tablets, Enzalutamide Soft Capsules
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
This phase I/II tests the safety, side effects and best dose of ruxolitinib in combination with enzalutamide and how well it works in treating patients with prostate cancer that remains despite blocking hormone production…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT06616155
- Testing
- Biopsy, Biospecimen Collection, Bone Scan
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
The study aims to assess the safety and tolerability of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer, and determine the recommended Phase II dose (RP2D); To evaluate of the efficacy of…
- Trial name
- NCT07407283
- Testing
- SHR-4394, Rezvilutamide, HRS-5041 Tablets
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.